DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Chart source: Finviz. Click opens TVTX quote page.
TVTX
Update: Jan 13, 2026 (PDUFA eve / after-hours volatility)
Travere Therapeutics – volatility update ahead of FILSPARI FSGS PDUFA
Super cautious note: what is confirmed vs what is still unknown. This is educational context, not a prediction.
Last close / after-hours (snapshot)
Regular close: $34.58 (Jan 12, 2026)
After-hours print (example feed): ~ $22.3 (very volatile)
After-hours volume (one feed): ~ 400.5K shares
Note: after-hours data can differ by venue/feed and can change quickly. Use your broker feed as the reference.
What the company officially said (confirmed)
PDUFA target date (FSGS sNDA): Jan 13, 2026
FDA information requests: company says FDA asked for more to characterize clinical benefit; responses submitted; currently under agency review
Preliminary commercial snapshot: FY25 U.S. net product sales ~ $410M; Q4 ~ $127M; year-end cash + marketable securities ~ $323M (preliminary)
Source is the company’s Jan 12, 2026 release and related SEC filing.
Focus
Today is about one thing: uncertainty around the FDA decision timing/outcome for the FILSPARI FSGS sNDA. The company explicitly highlighted FDA information requests right before the target date.
Warning
Maximum caution: after-hours moves can invalidate stops or create heavy slippage depending on broker/order settings and liquidity. Until an official FDA/company update is released, facts are limited.
EN
IT
Why moving
TVTX sold off sharply after-hours following a company update published right ahead of the FSGS PDUFA target date. The key line: the company said it recently received FDA information requests to further characterize clinical benefit, submitted responses, and those responses are under review.
What happened (confirmed vs unknown)
- Confirmed: company release + 8-K filed; PDUFA target date stated; FDA information requests disclosed; preliminary commercial/cash snapshot provided.
- Not confirmed (yet): there is no official FDA outcome in this note. No one outside FDA/company knows the final decision until it’s released.
- Market mechanism: after-hours liquidity is thinner, so moves can look “too big” vs the amount of actual shares traded.
Market view (cautious)
This is a classic binary-risk setup. The “information request” language increases uncertainty, but it is not, by itself, a final verdict. The only responsible stance right now is to treat the situation as high volatility / high headline risk until an official update lands.
What to watch next
- Official company press release / SEC filing if an FDA decision is received.
- FDA timing: decisions can come at various times; absence of news early does not confirm any outcome.
- Risk framing: gap behavior can persist into the open; do not assume “normal” price action immediately.
Perché si muove
TVTX ha avuto un crollo violento in after-hours dopo un update aziendale pubblicato a ridosso della data PDUFA (FSGS). La riga chiave: la società dice di aver ricevuto richieste di informazioni dalla FDA per “caratterizzare meglio il beneficio clinico”, di aver risposto, e che le risposte sono ora in review.
Cosa è successo (certo vs incerto)
- Certo: comunicato + 8-K depositato; PDUFA target date indicata; disclosure su richieste FDA; numeri preliminari su vendite/cassa.
- Non certo (ancora): in questa nota non esiste un esito ufficiale FDA. L’esito lo si conosce solo quando esce un aggiornamento ufficiale.
- Meccanica di mercato: in after-hours la liquidità è più sottile e i movimenti possono amplificarsi anche con volumi non enormi.
Vista di mercato (super cauta)
Questa è una situazione a rischio binario. La frase sulle “information requests” aumenta l’incertezza, ma da sola non è un verdetto. L’unica impostazione responsabile è trattare il tutto come alta volatilità / alto rischio headline fino a comunicazione ufficiale.
Cosa guardare adesso
- Press release / filing SEC se arriva la decisione FDA.
- Tempistiche: la decisione può uscire a orari diversi; il “silenzio” nelle prime ore non significa nulla.
- Gestione rischio: i gap e lo slippage possono continuare anche in apertura; non assumere subito un ritorno alla “normalità”.
Run-Up Strategy Focus (educational)
In biotech, the highest volatility often clusters around binary catalysts. A “run-up” approach (when appropriate) focuses on the pre-event window rather than the decision itself. This does not remove risk, but it can reduce exposure to the most extreme outcome swings.
Disclaimer
This note is for informational/educational purposes only and reflects a cautious interpretation of publicly available sources linked above. It is not investment advice, not a solicitation, and not a recommendation. Biotech events can be binary and extremely volatile; prices can gap and orders can experience slippage, especially outside regular hours. Always verify information with official releases/filings and use your own judgment.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
